Concordia International Corp (CXR.TO)

This fits into her strategy of growth by acquisition. They have been very successful and have made several acquisitions in the last little while. Probably one of the best performing stocks in healthcare. Great management.

A great company. We are moving into a world of slow growth because of demographics. Growth is going to be in the new, new things such as pharmaceuticals, healthcare, technology and some consumer products. It is probably not going to be the old-line, mundane industries. Thinks it is going to come under increasing buying interest from large cap managers. Once we get over this turbulence, he can see this going to $120-$130 very quickly.

Healthcare stocks can do quite well during the summer. They are less correlated to the market and are lower beta. This is a defensive sector. From the end of May onwards, the chart shows higher highs and higher lows. You can trade this trend channel all the way through to the end of the period of seasonal strength. He sees nothing wrong with this stock.

He thinks that this stock is wonderful. It is in a major uptrend. The 40 week moving average is well below it, It is a recent listing with a short history, so it is hard to analyze it. If you are a long term holder stick around.

Patient Home Monitoring (PHM-X) or Concordia Health (CXR-T)? 2 different business models. This is pharmaceuticals where Patient Home Monitoring is services. This is a much better company for investors as it is bigger, has more revenue, more established and has been around much longer.

The whole health/biotech sector has been extremely hot over the last year. Some analysts think this is the next bubble candidate. A consolidator and has been doing very well. Execution is good and they have been able to do accretive deals. If you want to invest in the sector, he would suggest you wait for a pullback.

Chart shows a long uptrend with a pretty big move early this year. There was a correction to take out part of that move, but it is starting to move up again. This is obviously a stock that has a lot of excitement behind it. The angle of the ascent has increased substantially. If you own don’t Sell as this is starting to break the trend line.

Great chart. He doesn't like roll up stories though. Prefers organic growth instead of acquisition growth. Not a name he would take a look at.

One of the healthcare stocks that has been a real rock star over the last year or so. They benefit from a better tax rate, because of tax inversion, and they have been acquiring firms giving them a multiple pick up. Scores well on price momentum, but valuation is not there yet. Rollup’s tend to be difficult to value because they are constantly acquiring other companies, and the cash flow is always in the future. Trading at 77X on a PE basis and 31X EBITDA.

This has done very well. It has been fantastic at growing the business from just having a couple of small drugs to where they have made bigger and bigger acquisitions. They’ve guided the market that they are looking at 3 different acquisitions now, where they hope that one of those will close in the 2^nd half of this year. They have a very good platform. There has been talk of them being acquired by a US company for tax inversion benefits.

A great company and there are still more acquisitions to go. Expects there will be new developments in the not too distant future. Over the next 12 months he could see it going to $110-$115 quite easily

An incredible Canadian success story, but has been predicated upon growth by acquisition. The healthcare space is quite hot right now. Because they have demonstrated their ability to acquire, they have access to capital markets. As long as that doesn’t shut down, the company will continue to be very acquisitive and very successful.

A healthcare company and has had a parabolic run. There is a bit of consolidation here, which suggests a bit of a pullback could occur within the immediate term. It is finding support at $78, but there could be more downside risk. He is seeing momentum indicators trend downwards, so that puts the weight towards the downside in the intermediate-term. You could probably find better opportunities elsewhere. (See Top Picks.)

Chart shows a sharp upward movement off the regular trend line earlier this year. Now starting to trend sideways after a bit of a correction. This is acting very healthy. He thinks you could take a chance.

You need to be cautious on this. A very crowded trade and has had a phenomenal run. As an investor he is always cautious about crowded trades. Also, understanding the acquisitions they are making can be difficult.